PAI-1, tPA, TFPI and HEECs in Uterine Hemostasis
The Role of Plasminogen Activator Inhibitor-1 (PAI-1), Tissue Plasminogen Activator (tPA), Tissue Factor Pathway Inhibitor (TFPI), and Endometrial Endothelial Cells in Uterine Hemostasis in Humans
Oregon Health and Science University
70 participants
Jul 12, 2023
INTERVENTIONAL
Conditions
Summary
The purpose of the study is to learn more about the role of blood clotting factor proteins and cells in menstrual (period) bleeding. The investigators are hoping to identify differences in these proteins and cells in the menstrual blood of individuals with heavy periods compared to menstruating individuals who do not have heavy periods.
Eligibility
Inclusion Criteria1
- Regularly menstruating participants between 18-45 years of age
Exclusion Criteria8
- Pregnancy within 3 months of enrollment
- Lactating at the time of enrollment
- Hormonal contraceptive use or use of the copper intrauterine device (IUD)
- Antifibrinolytic use
- Inherited or acquired bleeding disorder or anticoagulant use
- Known structural cause of HMB
- Inability to complete PBACs
- Unwilling to refrain from sexual intercourse for the two weeks prior to endometrial biopsy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will provide daily samples of menstrual blood for a single cycle and undergo a single endometrial biopsy for HEEC culture.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05862805